Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Health

Results: 1549-1560 of 9208

Business Wire logo

ICON’s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership

Business Wire logo

Bial Achieves Key Milestone in Phase 2b ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease

PR Newswire associated0

Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

BIOSeedin Winter Innovation Partnering Summit: J.P.Morgan Spotlight

Asthma and Allergy Drug Development Is Failing Too Often--A Translational Reset Is Needed: HKEY-AIRx™1.0

PR Newswire associated0

Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

3Shape appoints Rasmus Hannemann as Senior Vice President, Portfolio & Product Strategy

PR Newswire associated0

The European Commission extended the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union for use in pediatric patients under 2 years of age

The European Investment Bank (EIB) provides €20 million in financing to SamanTree Medical, a leader in surgical imaging innovation. The financing supports the development of an advanced confocal microscopy scanner for rapid imaging of the internal microstructure of tissue samples during surgical procedures, R&D and continued development and advancement of the company's Histolog® Scanner, the first and only medical imaging device featuring massively parallel confocal microscopy. Shown: Alessandro Izzo, EIB Director (left) and Olivier Delporte, CEO of SamanTree Medical (right).

EIB Provides €20 Million in Financing to SamanTree Medical for Real-Time Microscopy for Surgical Procedures

PR Newswire associated0

ICP DAS-BMP at WHX Dubai 2026 Spotlights Low-Migration and Low-Friction TPU

Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)

Change of date for publication of the year-end report for the financial year 2025

  • Prev Page
  • 1
  • 2
  • …
  • 129
  • 130
  • 131
  • …
  • 767
  • 768
  • Next Page

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2026

Terms of Use

Privacy Policy

Contact Us